News

TB R&D Update: Podcast Interview with Dr. Iwao Ojima

Dr. Iwao Ojima

Listen to Iwao Ojima Podcast

Dr. Iwao Ojima is a Distinguished Professor and Director of the Institute of Chemical Biology and Drug Discovery at Stony Brook University. His group recently published a paper in PLOS One entitled A Trisubstituted Benzimidazole Cell Division Inhibitor with Efficacy against Mycobacterium tuberculosis.

In this interview, Dr. Ojima discusses how he transitioned from working on Taxol, the anticancer compound to TB growth inhibitors, specifically benzimidazole compounds. Tri-substituted benzimidazoles have excellent activity against M.tb, reducing bacterial loads in mouse models by over 6 logs. They are especially interesting because of their mechanism of action; benzimidazoles target the FtsZ ring and disrupt cell division. Due to importance of cell division as a cellular process, resistance against benzimidazole compounds has yet to be observed. Furthermore, the compounds are equally potent against MDR and XDR-TB. Dr. Ojima is currently collaborating with Sanofi on preclinical development of the benzimidazole compounds.

In addition to discussing the promising benizimidazole compounds, Dr. Ojima expressed his thoughts on the current landscape of TB research. According to Dr. Ojima, developing a TB vaccine is of utmost importance. Prevention is preferable to treatment; if researchers develop an effective vaccine, the incidence and burden of the disease would substantially decrease. Dr. Ojima also stated that the expected profitability of TB drugs is a challenge for drug development. Since many TB patients are in middle to low income countries, TB drugs are not expected to be highly profitable. He stressed the importance of organizations like the Gates Foundation and TB Alliance for addressing the need for cheap anti-tubercular drugs.

Related Links

A Trisubstituted Benzimidazole Cell Division Inhibitor with Efficacy against Mycobacterium tuberculosis

Dr. Iwao Ojima profile

Institute of Chemical Biology and Drug Discovery

Additional TB R&D News

TB Lung Infection Causes Changes in the Diversity of Gut Bacteria in Mice

Diagnosis of Childhood Tuberculosis and Host RNA Expression in Africa

Diagnostic Accuracy of a Point-of-Care Urine Test for Tuberculosis Screening Among Newly-Diagnosed HIV-Infected Adults

More News
30 Mar 2021
Médecins Sans Frontières (MSF) published a press release on World TB Day 2021 announcing their clinical trial, TB-Practecal , investigating novel treatment for MDR-TB has stopped enrolling earlier than originally planned due to promising results. The trial's independent data safety and monitoring...
3 Feb 2021
Last week, the World Health Organization (WHO) held a consultation to discuss the definition of extensively drug resistant (XDR) tuberculosis. The meeting was held to discuss novel treatment regimens and diagnostics for drug-resistant TB and determine its impact on the definition of XDR-TB. The...
10 Dec 2020
The Stop TB Partnership Working Group on New TB Vaccines (WGNV), Working Group on New TB Drugs (WGND), and New Diagnostics Working Group (NDWG) are developing an online course specifically designed for advocates and affected communities to provide a base of knowledge in TB research and to generate...